| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. |
| 臺大學術典藏 |
2022-09-15T01:08:55Z |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
|
Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; Chia-Chi Lin; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. |
| 臺大學術典藏 |
2022-08-10T02:37:40Z |
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
|
Garrido P.; Adjei A.A.; Bajpai J.; Banerjee S.; Berghoff A.S.; Choo S.P.; Felip E.; Furness A.J.S.; Garralda E.; Haanen J.; Letsch A.; Linardou H.; Peters S.; Sessa C.; Tabernero J.; Tsang J.; CHIH-HSIN YANG; Garassino M.C. |
| 臺大學術典藏 |
2022-08-10T02:37:38Z |
Female leadership in oncology�Xhas progress stalled? Data from the ESMO W4O authorship and monitoring studies
|
Berghoff A.S.; Sessa C.; CHIH-HSIN YANG; Tsourti Z.; Tsang J.; Tabernero J.; Peters S.; Linardou H.; Letsch A.; Haanen J.; Garralda E.; Garassino M.C.; Furness A.J.S.; Felip E.; Dimopoulou G.; Dafni U.; Choo S.P.; Banerjee S.; Bajpai J.; Adjei A.A.; Garrido P. |
| 臺大學術典藏 |
2022-08-10T02:37:38Z |
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial
|
Zhou C.; Ramalingam S.S.; Kim T.M.; Kim S.-W.; CHIH-HSIN YANG; Riely G.J.; Mekhail T.; Nguyen D.; Garcia Campelo M.R.; Felip E.; Vincent S.; Jin S.; Griffin C.; Bunn V.; Lin J.; Lin H.M.; Mehta M.; J?nne P.A. |
| 臺大學術典藏 |
2022-08-10T02:37:38Z |
Brigatinib Versus Crizotinib in ALK Inhibitor�VNaive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
|
Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. |
| 臺大學術典藏 |
2022-06-27T06:59:45Z |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Su W.-C.; Mok T.; Scagliotti G.V.; Spigel D.R.; Viraswami-Appanna K.; Chen Z.; Passos V.Q.; Shaw A.T. |
| 臺大學術典藏 |
2022-06-27T06:59:36Z |
Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park K.; J?nne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. |
| 國立成功大學 |
2022 |
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer
|
Santoro, A.;Su, W.-C.;Navarro, A.;Simonelli, M.;CH, Yang J.;Ardizzoni, Ardizzoni A.;Barlesi, F.;Hyoung, Kang J.;DiDominick, S.;Abdelhady, Abdelhady A.;Chen, X.;Stammberger, U.;Felip, E. |
| 國立成功大學 |
2022 |
Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
|
Gupta, S.;Strohbehn, I.A.;Wang, Q.;Hanna, P.E.;Seethapathy, R.;Prosek, J.M.;Herrmann, S.M.;Abudayyeh, Abudayyeh A.;Malik, A.B.;Loew, S.;Carlos, Carlos C.A.;Chang, W.-T.;Beckerman, P.;Mithani, Z.;Shah, C.V.;Renaghan, A.D.;de, Seigneux S.;Campedel, L.;Kitchlu, A.;Shin, D.S.;Coppock, G.;Lumlertgul, N.;Garcia, P.;Ortiz-Melo, D.I.;Rashidi, A.;Sprangers, B.;Aggarwal, V.;Benesova, K.;Jhaveri, K.D.;Cortazar, F.B.;Weins, A.;Zuo, Y.;Mooradian, Mooradian M.J.;Reynolds, K.L.;Leaf, D.E.;Sise, M.E.;Salem, J.-E.;Bagnis, C.I.;Singh, H.;Motwani, S.S.;Murakami, N.;Tio, M.C.;Mothi, S.S.;Selamet, U.;Schmidt-Ott, K.M.;Chang, W.;Wanchoo, R.;Khanin, Y.;Hirsch, J.S.;Sakhiya, V.;Stalbow, D.;Wu, S.;Ostermann, M.;Seylanova, N.;Cennamo, A.;Rigg, A.;Shaunak, N.;Kibbelaar, Z.A.;Deshpande, P.;Seethapathy, H.S.;Lee, M.;Strohbhen, I.A.;Isik, B.;Glezerman, I.G.;Chandra, S.;Madhavan, S.M.;Owen, D.H.;Husain, M.;Mini, S.;Anand, S.;Kaghazchi, A.;Rangarajan, S.;Cherry, G.;Hsu, R.K.;Kisel, A.;Kansal, S.K.;Albert, N.;Carter, K.;Donley, V.;Young, T.;Cigoi, H.;Koessler, T.;Wauters, E.;Eijgelsheim, M.;Pagan, J.A.;Hogan, J.J.;Mamlouk, O.;Lin, J.S.;Page, V.;Short, Short S.A.P.;Gaughan, E.M.;Soler, M.J.;Garc�a-Carro, Carro C.;Bermejo, S.;Felip, E.;Mu�oz-Couselo, E.;Carreras, M.J.;Consortium, ICPi-AKI |
| 臺大學術典藏 |
2021-05-02T03:29:22Z |
Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park K.; J?nne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
|
Tan D.S.-W.;Leighl N.B.;Riely G.J.;Chih-Hsin Yang;Sequist L.V.;Wolf J.;Seto T.;Felip E.;Aix S.P.;Jonnaert M.;Pan C.;Tan E.Y.;Ko J.;Moody S.E.;Kim D.-W.; Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. |
| 臺大學術典藏 |
2021-04-23T05:56:28Z |
Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
|
Paik P.K.;Felip E.;Veillon R.;Sakai H.;Cortot A.B.;Garassino M.C.;Mazieres J.;Viteri S.;Senellart H.;Van Meerbeeck J.;Raskin J.;Reinmuth N.;Conte P.;Kowalski D.;Cho B.C.;Patel J.D.;Horn L.;Griesinger F.;Han J.-Y.;Kim Y.-C.;Chang G.-C.;Tsai C.-L.;Chih-Hsin Yang;Chen Y.-M.;Smit E.F.;Van Der Wekken A.J.;Kato T.;Juraeva D.;Stroh C.;Bruns R.;Straub J.;Johne A.;Scheele J.;Heymach J.V.;Le X.; Paik P.K.; Felip E.; Veillon R.; Sakai H.; Cortot A.B.; Garassino M.C.; Mazieres J.; Viteri S.; Senellart H.; van Meerbeeck J.; Raskin J.; Reinmuth N.; Conte P.; Kowalski D.; Cho B.C.; Patel J.D.; Horn L.; Griesinger F.; Han J.-Y.; Kim Y.-C.; Chang G.-C.; Tsai C.-L.; CHIH-HSIN YANG; Chen Y.-M.; Smit E.F.; van der Wekken A.J.; Kato T.; Juraeva D.; Stroh C.; Bruns R.; Straub J.; Johne A.; Scheele J.; Heymach J.V.; Le X. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor�VNaive ALK-Positive Non�VSmall Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
|
Camidge D.R.;Kim H.R.;Ahn M.-J.;Chih-Hsin Yang;Han J.-Y.;Hochmair M.J.;Lee K.H.;Delmonte A.;Garc?A Campelo M.R.;Kim D.-W.;Griesinger F.;Felip E.;Califano R.;Spira A.;Gettinger S.N.;Tiseo M.;Lin H.M.;Gupta N.;Hanley M.J.;Ni Q.;Zhang P.;Popat S.; Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. |
| 中山醫學大學 |
2021 |
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park, K; Janne, PA; Kim, DW; Han, JY; Wu, MF; Lee, JS; Kang, JH; Lee, DH; Cho, BC; Yu, CJ; Pang, YK; Felip, E; Kim, H; Baek, E; Noh, YS |
| 臺大學術典藏 |
2020-12-02T02:34:19Z |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
|
Tan E.-H.;Ramlau R.;Pluzanska A.;Kuo H.-P.;Reck M.;Milanowski J.;Au J.S.-K.;Felip E.;Pan-Chyr Yang;Damyanov D.;Orlov S.;Akimov M.;Delmar P.;Essioux L.;Hillenbach C.;Klughammer B.;Mcloughlin P.;Baselga J.; Tan E.-H.; Ramlau R.; Pluzanska A.; Kuo H.-P.; Reck M.; Milanowski J.; Au J.S.-K.; Felip E.; PAN-CHYR YANG; Damyanov D.; Orlov S.; Akimov M.; Delmar P.; Essioux L.; Hillenbach C.; Klughammer B.; McLoughlin P.; Baselga J. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
|
Ranson M.;Ghiorghiu S;Dickinson P.A;Brown K.H;Cantarini M;Frewer P;Kim J.-H;Felip E;Haggstrom D;Horn L;Su W.-C;Kim S.-W;Ahn M.-J;Ramalingam S.S;Ohe Y;Planchard D;Kim D.-W;Chih-Hsin Yang;J?nne P.A; Jänne P.A; Chih-Hsin CHIH-HSIN YANG; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial
|
Lux-Lung 5 Investigators;Serwatowski P;Kazarnowicz A;Jaskiewicz P;Palomino O.L.M;Pantigoso W.R;Barreda R.L.A;S?nchez J.F.S;Gans S;Herder G;Dingemans A.-M;Stigt J;Aerts J;Baca O.P;Luna G.A;Perez J.L.G;Delgado F.G;Cruciani G;Ceresoli G.L;Platania M;Milandri C;Gridelli C;Bearz A;Bidoli P;Migliorino M.R;Stemmer S;Gottfried M;Onn A;Nagarkar R.V;Dadhich H;Sharma L;Venkatesan S;Jain M;Prabhash K;Sarosi V;Strausz J;Tehenes S;Mark Z;Wiewrodt R;Dickgreber N;Huber R;Von Pawel J;Laack E;Keilholz U;Faehling M;Wehler T;Thomas M;Coudert B;Rotarski M;Gervais R;Fournel P;Bennouna J;Planchard D;Perol M;Sibilot D.M;Zalcman G;Chouaid C;Cadranel J;Alanko T;Riska H;Zadra C.A;Garicochea B;Zereu M;Lu S;Zhang Y;Huang J;Feng J;Qin S;Cheng Y;Liu X;Wu Y;Lin X;Thropay J;Meza L;Gurtler J;Summers Y;Upadhyay S;Brown E;Talbot T;Toy E;Spicer J;Popat S;Mitra S;Shah R;Polishchuk I;Bondarenko I;Ponomarova O;Popovych O;Vinnyk Y;Hsieh R.-K;Ho C.-L;Huang M.-S;Su W.-C;Tsao T.C.-Y;Chang G.-C;Tsai Y.-H;Chen Y.-M;Hsia T.-C;Yang C.-H;Kim Y.-C;Han J.-Y;Kim J.-H;Park K;Kim S.-W;Kim D.-W;Felip E;Cobo M;Lianes P;Campelo R.G;Camps C;Larriba J.L.G;Garrido P;Ragulin Y;Orlov S;Karaseva N;Lubennikov V;Jassem J;Szczesna A;Huang C;Wang J;Zhou C;Vercauter P;Delval L;Lambrechts M;Galdermans D;Carestia L;Bustin F;Humblet Y;Greil R;Mainwaring P;Crombie C;Underhill C;Parente P;Mclachlan S.-A;Richardet M;Blajman C;Zarba J.J;Recondo G;Martin C.M;Bagnes C;Planchard D;Chand V.K;Wang B;Zhou C;Wiewrodt R;Vinnyk Y;Strausz J;Lu S;Liu X;Kim D.-W;Grossi F;Feng J.-F;De Marinis F;Chouaid C;Chen Y.-M;Bennouna J;Kim J.-H;Park K;Chih-Hsin Yang;Schuler M; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators; Schuler M; CHIH-HSIN YANG; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial
|
Lux-Lung 5 Investigators;Serwatowski P;Kazarnowicz A;Jaskiewicz P;Palomino O.L.M;Pantigoso W.R;Barreda R.L.A;S?nchez J.F.S;Gans S;Herder G;Dingemans A.-M;Stigt J;Aerts J;Baca O.P;Luna G.A;Perez J.L.G;Delgado F.G;Cruciani G;Ceresoli G.L;Platania M;Milandri C;Gridelli C;Bearz A;Bidoli P;Migliorino M.R;Stemmer S;Gottfried M;Onn A;Nagarkar R.V;Dadhich H;Sharma L;Venkatesan S;Jain M;Prabhash K;Sarosi V;Strausz J;Tehenes S;Mark Z;Wiewrodt R;Dickgreber N;Huber R;Von Pawel J;Laack E;Keilholz U;Faehling M;Wehler T;Thomas M;Coudert B;Rotarski M;Gervais R;Fournel P;Bennouna J;Planchard D;Perol M;Sibilot D.M;Zalcman G;Chouaid C;Cadranel J;Alanko T;Riska H;Zadra C.A;Garicochea B;Zereu M;Lu S;Zhang Y;Huang J;Feng J;Qin S;Cheng Y;Liu X;Wu Y;Lin X;Thropay J;Meza L;Gurtler J;Summers Y;Upadhyay S;Brown E;Talbot T;Toy E;Spicer J;Popat S;Mitra S;Shah R;Polishchuk I;Bondarenko I;Ponomarova O;Popovych O;Vinnyk Y;Hsieh R.-K;Ho C.-L;Huang M.-S;Su W.-C;Tsao T.C.-Y;Chang G.-C;Tsai Y.-H;Chen Y.-M;Hsia T.-C;Yang C.-H;Kim Y.-C;Han J.-Y;Kim J.-H;Park K;Kim S.-W;Kim D.-W;Felip E;Cobo M;Lianes P;Campelo R.G;Camps C;Larriba J.L.G;Garrido P;Ragulin Y;Orlov S;Karaseva N;Lubennikov V;Jassem J;Szczesna A;Huang C;Wang J;Zhou C;Vercauter P;Delval L;Lambrechts M;Galdermans D;Carestia L;Bustin F;Humblet Y;Greil R;Mainwaring P;Crombie C;Underhill C;Parente P;Mclachlan S.-A;Richardet M;Blajman C;Zarba J.J;Recondo G;Martin C.M;Bagnes C;Planchard D;Chand V.K;Wang B;Zhou C;Wiewrodt R;Vinnyk Y;Strausz J;Lu S;Liu X;Kim D.-W;Grossi F;Feng J.-F;De Marinis F;Chouaid C;Chen Y.-M;Bennouna J;Kim J.-H;Park K;Chih-Hsin Yang;Schuler M; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators; Schuler M; CHIH-HSIN YANG; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer
|
Barlesi F.;Satouchi M;Iannotti N;Chih-Hsin Yang;Nokihara H;Guo M;Olivo M;Kim J.-H;Spigel D.R;Felip E;Katakami N; Katakami N; Felip E; Spigel D.R; Kim J.-H; Olivo M; Guo M; Nokihara H; CHIH-HSIN YANG; Iannotti N; Satouchi M; Barlesi F. |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer
|
Barlesi F.;Satouchi M;Iannotti N;Chih-Hsin Yang;Nokihara H;Guo M;Olivo M;Kim J.-H;Spigel D.R;Felip E;Katakami N; Katakami N; Felip E; Spigel D.R; Kim J.-H; Olivo M; Guo M; Nokihara H; CHIH-HSIN YANG; Iannotti N; Satouchi M; Barlesi F. |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
|
Syrigos K; van Meerbeeck J.P; van Zandwijk N; Chih-Hsin CHIH-HSIN YANG; Zhou C; Vokes E.; Vokes E.;Zhou C;Chih-Hsin Yang;Van Zandwijk N;Van Meerbeeck J.P;Syrigos K;Smit E.F;P?rol M;Papotti M;Novello S;Mornex F;Moniuszko M;Marabelle A;Huber R.M;Garrido P;Fennell D;Felip E;Crin? L;Brustugun O.T;Wu Y.-L;Reck M;Peters S;Nicolson M;Nakagawa K;Gray J.E;Dingemans A.-M.C;Manegold C; Manegold C; Dingemans A.-M.C; Gray J.E; Nakagawa K; Nicolson M; Peters S; Reck M; Wu Y.-L; Brustugun O.T; Crinò L; Felip E; Smit E.F; Pérol M; Papotti M; Fennell D; Garrido P; Huber R.M; Marabelle A; Moniuszko M; Mornex F; Novello S |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
|
Syrigos K; van Meerbeeck J.P; van Zandwijk N; Chih-Hsin CHIH-HSIN YANG; Zhou C; Vokes E.; Vokes E.;Zhou C;Chih-Hsin Yang;Van Zandwijk N;Van Meerbeeck J.P;Syrigos K;Smit E.F;P?rol M;Papotti M;Novello S;Mornex F;Moniuszko M;Marabelle A;Huber R.M;Garrido P;Fennell D;Felip E;Crin? L;Brustugun O.T;Wu Y.-L;Reck M;Peters S;Nicolson M;Nakagawa K;Gray J.E;Dingemans A.-M.C;Manegold C; Manegold C; Dingemans A.-M.C; Gray J.E; Nakagawa K; Nicolson M; Peters S; Reck M; Wu Y.-L; Brustugun O.T; Crinò L; Felip E; Smit E.F; Pérol M; Papotti M; Fennell D; Garrido P; Huber R.M; Marabelle A; Moniuszko M; Mornex F; Novello S |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
